Olmesartan in crisis? Removal of discussion event schedule
The destiny of olmesartan – whose safety letter is distributed in Korea as removed from the insurance benefit by the French Agency for the Safety of Health Products(ANSM) due to suspicion in safety and validity – is expected to be decided soon.
The Ministry of Food and Drug Safety will hold the ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
